References
- Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.
- Skopek R, Palusińska M, Kaczor-Keller K, Pingwara R, Papierniak-Wyglądała A, Schenk T, et al. Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. Int J Mol Sci. 2023;24(6).
- Sajid R, Moiz B, Ali N, Kamran N, Adil AN, Shaikh U, et al. Therapeutic outcomes of older patients with acute myeloid leukemia. Saudi Med J. 2010;31(5):533–8.
- DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
- Vachhani P, Flahavan EM, Xu T, Ma E, Montez M, Gershon A, et al. Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US. Oncologist. 2022;27(11):907–18.
- Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8(3):705–11.
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017 2017//.
- Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.
- Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, et al. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. Cancers (Basel). 2022;14(8).
- Mirgh S, Sharma A, Shaikh M, Kadian K, Agrawal N, Khushoo V, et al. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021;11(3):290–302.
- Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. American Journal of Hematology. 2021;96(2):208–17.
- Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, et al. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Cancer. 2023;129(7):992–1004.